Empowering Patients in Research – First Insights from 444 Participants in the PATRE SYNGAP1 Registry

We are proud to share that our work on the PATRE SYNGAP1 Registry was presented at the International Epilepsy Congress (IEC) 2025 in Lisbon.

Our poster, presented by Kirsten Eschermann, was selected for the prestigious ILAE YES (Young Epilepsy Section) Poster Tour – Poster #363.

Why this matters

The PATRE SYNGAP1 Registry was created together with families, clinicians, and researchers as part of the EURAS Horizon Europe consortium. It is a multilingual, app-based platform that empowers families to directly contribute health information and experiences. This data helps researchers understand SYNGAP1-related encephalopathy and accelerates the path towards new therapies.

Key results from 444 SYNGAP1 participants

🔹 Developmental milestones are consistently delayed:

• Sitting unsupported: ~12 months
• Walking independently: ~28 months
• First two-word sentences: ~47 months

🔹 Functional outcomes (PEDI-CAT):

• Daily activities & Social/Cognitive: ~4th percentile
• Mobility: ~12th percentile

🔹 HPO-based phenotyping (systematic clinical feature mapping):

• High frequency of neurodevelopmental features (motor delay, speech delay, autistic behaviors)
• Frequent epilepsy-related phenotypes (generalized motor & non-motor seizures, absence seizures, myoclonic-atonic seizures)
• Behavioral and sensory features (hyperactivity, self-injury, abnormal pain sensation, sleep disturbance)
• Comorbidities including vision problems, scoliosis, growth abnormalities

This comprehensive HPO dataset provides one of the most detailed phenotypic landscapes of SYNGAP1 to date, demonstrating the power of structured, patient-driven data collection.

Looking ahead

The PATRE platform is designed to be a model for rare epilepsies and neurodevelopmental disorders. By combining patient engagement with standardized data elements, we are building a resource that will:

• Support preclinical models and therapeutic development
• Enable international collaboration across research groups
• Provide families with a stronger voice in research

We are delighted to share that our abstract

“Empowering Patients in Research: Insights from the World’s Largest SYNGAP1 Registry”

has been awarded the Mac Keith Press Best Abstract Award 2025 at this year’s EACD/IAACD Congress in Heidelberg.

This prestigious award honors the highest-rated abstract of the entire congress. With over 1,200 abstracts submitted from more than 80 countries, the selection process is highly competitive. The jury—appointed by Mac Keith Press, the nonprofit publisher of Developmental Medicine & Child Neurology—evaluates submissions based on originality, methodological quality, clinical relevance, and clarity of presentation. Our abstract was selected as the top submission of 2025.

The EACD/IAACD Congress is the world’s largest interdisciplinary conference on childhood disability. Held only every three years in cooperation with the International Alliance of Academies of Childhood Disability (IAACD), the event brings together clinicians, researchers, therapists, and family advocates from across the globe.

The award-winning abstract highlights the patient-centered approach of the SYNGAP1 Registry and its integration into PATRE and the EURAS project, showcasing how families’ active participation can drive scientific discovery in rare diseases.

We accepted the award on behalf of the entire team – but this recognition belongs to all collaborators who contributed their trust, time, and expertise to this shared effort.

A special thank you goes to the many SYNGAP1 families whose commitment made this research possible in the first place.

📎 Read also the official announcement on the EURAS website:

👉 www.euras-project.eu/news-events

PATRE is very proud to have co-initiated the HORIZON EUROPE consortium EURAS.

PATRE is responsible for the patient registries in the consortium together with the University of Magdeburg.

Here is the link to a press release (in German).

It was a honour to present the latest results of our SYNGAP1 medication questionnaire at the IEC 2023 ILAE IBE World Congress in Dublin.